Pluri IncNASDAQ:PLUR
- LAST PRICE5.0900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 5.0900
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PLUR |
|---|---|---|
| 09:32 ET | 124 | 5 |
| 12:39 ET | 4770 | 5.1 |
| 02:38 ET | 100 | 5.14 |
| 02:54 ET | 5200 | 5.18 |
| 03:52 ET | 125 | 5.09 |
Apr 8, 2024
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method, from 7:00AM ET on Monday Apr 08, 2024 by Dow Jones
7:00AM ET on Monday Apr 08, 2024 by Dow Jones
Mar 28, 2024
Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences, from 7:15AM ET on Thursday Mar 28, 2024 by Dow Jones
7:15AM ET on Thursday Mar 28, 2024 by Dow Jones
Mar 27, 2024
Pluri Inc. Announces 1-for-8 Reverse Share Split, from 7:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
7:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Pluri Inc | 26.6M | -1.1x | --- |
Forte Biosciences Inc | 26.2M | -0.6x | --- |
Serina Therapeutics Inc | 25.0M | -0.7x | --- |
BioVie Inc | 27.8M | -0.4x | --- |
Iterum Therapeutics PLC | 25.5M | -0.5x | --- |
Enlivex Therapeutics Ltd | 27.9M | -1.0x | --- |
Company Information
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Contact Information
- Headquarters
- Matam Park Building 5HAIFA, Israel 3508409
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Zalman Aberman
- President, Chief Executive Officer, Director
- Yaky Yanay
- Chief Financial Officer, Treasurer, Secretary
- Chen Franco-Yehuda
- Director
- Lorne Abony
- Independent Director
- Doron Birger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $26.6M |
|---|---|
Revenue (TTM) | $357.0K |
Shares Outstanding | 5.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.55 |
EPS | $-4.75 |
Book Value | $2.59 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | 74.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6,788.24% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
